Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer
Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer
Study evaluating weekly oral vinorelbine versus weekly paclitaxel in a population of patients with advanced breast cancer.
Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
85
Years old
Gender
Female
Therapeutic area :
Oncology
Disease :
Metastatic breast cancer
Study medication :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Start Date :
04 October 2012
End date :
05 September 2018
Study ID :
PM0259 CA 231 B0
EudraCT/CTIS number :
2012-003530-16
Send by email